MEDCL.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:35):

Stats
Today's Volume	121 673
Average Volume	67 809.00
Market Cap	360.10M
EPS	€0 ( 2023-12-18 )
Next earnings date	( €0 ) 2024-06-25
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-12.28
ATR14	€0.0370 (0.30%)

Volume Correlation

Long: -0.02 (neutral)

Short: -0.85 (strong negative)

Signal:(55.474) Neutral

Medincell SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medincell SA Correlation - Currency/Commodity

-0.78
( moderate negative )

-0.71
( moderate negative )

0.00
( neutral )

-0.70
( moderate negative )

0.38
( neutral )

0.28
( neutral )

Medincell SA Financials

Annual	2022
Revenue:	€9.89M
Gross Profit:	€13.66M (138.08 %)
EPS:	€-1.270

Q2	2023
Revenue:	€6.99M
Gross Profit:	€8.18M (117.11 %)
EPS:	€-0.290

Q4	2022
Revenue:	€3.86M
Gross Profit:	€5.95M (153.96 %)
EPS:	€-0.720

Q3	2022
Revenue:	€2.97M
Gross Profit:	€2.97M (100.00 %)
EPS:	€-0.360

Financial Reports:

No articles found.

Medincell SA

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.